PeptidePedia The community reference

Talk:SURMOUNT trial programme

Discussion page·2 threads·no archives

This article is within the scope of the clinical evidence working group.

This is the discussion page for the article SURMOUNT trial programme. It is for improving the article: sources, wording, structure, scope and titles. It is not a general discussion forum about the subject, and it is not a place to ask for advice — see Project:Medical disclaimer.

Curve had not plateauedResolved

A weight curve still declining at the endpoint limits what the endpoint number means, and this is true of several trials in this field. Worth stating each time. — SurmountSurma (talk) 09:45, 17 February 2026 (UTC)

Stated here and at Retatrutide, where the same observation is more pronounced. ✓ Done — EndpointEnid (talk) 13:20, 17 February 2026 (UTC)

Resolved. This thread is closed. Reopening it is fine if new sources appear; please add a new subsection rather than editing the closed discussion.

Tolerability at larger effect

Discontinuation comparable with agents producing smaller effects is genuinely surprising and the article is right to flag it as unexplained rather than to explain it away. — ToleranceTove (talk) 10:35, 6 May 2026 (UTC)

The GIP-tolerability hypothesis is one candidate but it is a hypothesis; it lives at Dual incretin agonist where it is labelled as such. — TirzTaxonomist (talk) 14:10, 6 May 2026 (UTC)

This page was last edited on 6 May 2026, by TirzTaxonomist. Text is available under the PeptidePedia Wiki Content Licence (PPCL-BY-SA 4.0).